For the first time, researchers have enticed transplants of embryonic stem
cell-derived motor neurons in the spinal cord to connect with muscles and partially
restore function in paralyzed animals. The study suggests that similar techniques
may be useful for treating such disorders as spinal cord injury, transverse myelitis,
amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy. The study was
funded in part by the NIH?s National Institute of Neurological Disorders and
Stroke (NINDS).
The researchers, led by Douglas Kerr, M.D., Ph.D., of The Johns Hopkins University
School of Medicine, used a combination of transplanted motor neurons, chemicals
capable of overcoming signals that inhibit axon growth, and a nerve growth factor
to attract axons to muscles. The report is published in the July 2006 issue of Annals
of Neurology.*
"This work is a remarkable advance that can help us understand how stem cells
might be used to treat injuries and disease and begin to fulfill their great
promise. The successful demonstration of functional restoration is proof of the
principle and an important step forward. We must remember, however, that we still
have a great distance to go," says Elias A. Zerhouni, Director of the National
Institutes of Health.
?This study provides a 'recipe' for using stem cells to reconnect the nervous
system,? says Dr. Kerr. "It raises the notion that we can eventually achieve
this in humans, although we have a long way to go."
In the study, Dr. Kerr and his colleagues cultured embryonic stem cells from
mice with chemicals that caused them to differentiate into motor neurons. Just
before transplantation, they added three nerve growth factors to the culture
medium. Most of the cells were also cultured with a substance called dibutyrl
cAMP (dbcAMP) that helps to overcome axon-inhibiting signals from myelin, the
substance that insulates nerve fibers in the spinal cord.
The cells were transplanted into eight groups of paralyzed rats. Each group
received a different combination of treatments. Some groups received injections
of a drug called rolipram under the skin before and after the transplants. Rolipram,
a drug approved to treat depression, helps to counteract axon-inhibiting signals
from myelin. Some animals also received transplants of neural stem cells that
secreted the nerve growth factor GDNF into the sciatic nerve (the sciatic nerve
extends from the spine down the back of the hind leg). GDNF causes axons to grow
toward it.
Three months after the transplants, the investigators examined the rats for
signs that the stem cell-derived neurons had survived and integrated with the
nervous system. The rats that had received the full cocktail of treatments — transplanted
motor neurons, rolipram, dbcAMP, and GDNF-secreting neural stem cells in the
sciatic nerve — had several hundred transplant-derived axons extending
into the peripheral nervous system, more than in any other group. The axons in
these animals reached all the way to the gastrocnemius muscle in the lower leg
and formed functional connections, called synapses, with the muscle. The rats
showed an increase in the number of functioning motor neurons and an approximately
50 percent improvement in hind limb grip strength by 4 months after transplantation.
In contrast, none of the rats given other combinations of treatments recovered
lost function.